Dossier assessment
Niraparib/abiraterone acetate (prostate cancer) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Niraparib/abiraterone acetate (prostate cancer) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Niraparib/abiraterone acetate (prostate cancer) – Benefit assessment according to §35a Social Code Book V
Drug assessment at a glance
-
Drug assessment at a glance
Niraparib/abiraterone acetate (prostate cancer) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with metastatic hormone-sensitive prostate cancer (mHSPC) and breast cancer-associated gene (BRCA)1/2 mutations (germline and/or somatic)
- Patients with newly diagnosed high-risk mHSPC and BRCA1/2 mutations (germline and/or somatic): added benefit not proven
- All other patients in the therapeutic indication: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
03-09-2026 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- A26-31
- Commission
- Commission awarded on 16.03.2026 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on 15.06.2026.
- DOI
https://doi.org/10.60584/A26-31_V1.1
Connected Projects
-
Dossier assessment
Niraparib/abiraterone acetate (prostate cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Addendum
Niraparib/abiraterone acetate (prostate cancer) – Addendum to Project A26-31
Status: Commission completed